-+ 0.00%
-+ 0.00%
-+ 0.00%

Antengene to present new preclinical data for autoimmune drug candidate ATG-207 at ACR 2026

PUBT·10/09/2026 02:48:59
Listen to the news
Antengene to present new preclinical data for autoimmune drug candidate ATG-207 at ACR 2026
  • Antengene flagged new preclinical results for ATG-207, an experimental autoimmune therapy, for presentation at the ACR 2026 meeting.
  • Results will be presented in a poster session on Nov. 9, 2026, in Orlando.
  • The data suggest ATG-207 can curb harmful T-cell activity while boosting immune-regulating cells, supporting a tolerance-restoring approach.
  • Animal studies indicated disease improvement across several autoimmune models, with repeat-dose testing showing the program was generally well tolerated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610082248PR_NEWS_USPR_____CN57714) on October 09, 2026, and is solely responsible for the information contained therein.